[O10] Oral Session 10　Cross-sectional Program
【E】

[O10-1] Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer

^○Makoto Tahara¹, Marcia S. Brose², Lin Shen³, Daniel S.W Tan⁴, Shivaani Kummar⁵, Jessica J. Lin^6,7, Ray Mcdermott⁸, Jordan Berlin⁹, Ulrik N. Lassen¹⁰, Serge Leyvraz¹¹, Jyoti D. Patel¹², Ricarda Norenberg¹³, Laura Dima¹⁴, Nicoletta Brega¹⁵, David S. Hong¹⁶, Alexander Drilon^17,18 (1.Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 2.Abramson Cancer Center of the University of Pennsylvania School of Medicine, Philadelphia, PA, USA, 3.Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China, 4.Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore, 5.Oregon Health & Science University, Portland, OR, USA, 6.Department of Medicine, Massachusetts General Hospital, Boston, MA USA, 7.Harvard Medical School, Boston, MA USA., 8.St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland, 9.Vanderbilt University Medical Center, Nashville, TN, USA, 10.Department of Oncology, Rigshospitalet, Copenhagen, Denmark, 11.Charité – Universitätsmedizin Berlin, Berlin, Germany, 12.Northwestern University, Chicago, IL, USA, 13.Chrestos Concept GmbH & Co. KG, Essen, Germany, 14.Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland, 15.Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, 16.The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 17.Memorial Sloan Kettering Cancer Center, New York, NY, USA, 18.Weill Cornell Medical College, New York, NY, USA)